Evidence map›Paper›PMID 38094241›Full record

ArticleEngineering biology2023

Protein engineering in the computational age: An open source framework for exploring mutational landscapes

Shirin Bamezai, Giovanni Maresca di Serracapriola, Freya Morris, Rasmus Hildebrandt, Marc Augustine Sojerido Amil, Sporadicate iGEM Team, Rodrigo Ledesma-Amaro

Abstract read
In one paragraph

Article in Engineering biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Computational Evidence for Digenic Contribution ofInternational journal of molecular sciences · 2025
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shirin BamezaiDepartment of Bioengineering and Imperial College Centre for Synthetic Biology Imperial College London London UK.
Giovanni Maresca di SerracapriolaDepartment of Bioengineering and Imperial College Centre for Synthetic Biology Imperial College London London UK.
Freya MorrisDepartment of Bioengineering and Imperial College Centre for Synthetic Biology Imperial College London London UK.
Rasmus HildebrandtFaculty of Natural Sciences Imperial College London London UK.
Marc Augustine Sojerido AmilDepartment of Bioengineering and Imperial College Centre for Synthetic Biology Imperial College London London UK.
Sporadicate iGEM Team
Rodrigo Ledesma-AmaroDepartment of Bioengineering and Imperial College Centre for Synthetic Biology Imperial College London London UK.ORCID https://orcid.org/0000-0003-2631-5898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of protein engineering has seen tremendous expansion in the last decade, with researchers developing novel proteins with specialised functionalities for a range of uses, from drug discovery to industrial biotechnology. The emergence of computational tools and high-throughput screening technology has substantially sped up the process of protein engineering. However, much of the expertise required to engage in such projects is still concentrated in the hands of a few specialised individuals, including computational biologists and structural biochemists. The international Genetically Engineered Machine (iGEM) competition represents a platform for undergraduate students to innovate in synthetic biology. Yet, due to their complexity, arduous protein engineering projects are hindered by the resources available and strict timelines of the competition. The authors highlight how the 2022 iGEM Team, 'Sporadicate', set out to develop InFinity 1.0, a computational framework for increased accessibility to effective protein engineering, hoping to increase awareness and accessibility to novel

Indexed as

biochemical engineeringsynthetic biology

Identifiers

PMID38094241
PMCPMC10715127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.